Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02958085 · ClinicalTrials.gov registry record · Phase 1
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
NCT02958085 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 96 participants.
The verdict
NCT02958085, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
Study Summary
This trial is conducted in The United States of America. The aim of this trial is to investigate Safety, Tolerability, Pharmacokinetics (the exposure of the trial drug in the body) and Pharmacodynamics (the effect of the investigated drug on the body) of Multiple Dosing of NNC0174-0833 in Subjects with Obesity or Overweight.
Interventions
- DRUG Placebo
- DRUG NNC0174-0833
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2016-11-04 |
| Est. Completion | 2018-01-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02958085
The ClinicalTrials.gov registry entry for NCT02958085 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02958085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02958085 about?
NCT02958085 is a clinical study titled "Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight". This trial is conducted in The United States of America. The aim of this trial is to investigate Safety, Tolerability, Pharmacokinetics (the exposure of the trial drug in the body) and Pharmacodynamics (the effect of the investigated drug on the body) of Multiple Dosing of NNC0174-0833 in Subjects w...
What is the current status of trial NCT02958085?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2016-11-04. Estimated completion is 2018-01-24.
What interventions are being tested in trial NCT02958085?
The interventions under investigation include: Placebo (DRUG), NNC0174-0833 (DRUG).
Who is sponsoring clinical trial NCT02958085?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.